Next Article in Journal
Saponins Isolated from Asparagus Induce Apoptosis in Human Hepatoma Cell Line HepG2 Through a Mitochondrial-Mediated Pathway
Previous Article in Journal
Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Future of Personalized Medicine in Non-Small-Cell Lung Cancer

Department of Oncology, McGill University Health Centre, Montreal, QC, Canada
Curr. Oncol. 2012, 19(s1), 86; https://doi.org/10.3747/co.19.1049
Submission received: 8 March 2012 / Revised: 5 April 2012 / Accepted: 2 May 2012 / Published: 1 June 2012

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

The remarkable progress we are witnessing in the understanding of the molecular biology and signalling pathways of non-small-cell lung cancer (NSCLC) cells has resulted in ErbB-targeted therapies and many other targeted agents, especially Alk inhibitors, now in clinical trials [...]

Share and Cite

MDPI and ACS Style

Hirsh, V. Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Curr. Oncol. 2012, 19, 86. https://doi.org/10.3747/co.19.1049

AMA Style

Hirsh V. Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Current Oncology. 2012; 19(s1):86. https://doi.org/10.3747/co.19.1049

Chicago/Turabian Style

Hirsh, V. 2012. "Future of Personalized Medicine in Non-Small-Cell Lung Cancer" Current Oncology 19, no. s1: 86. https://doi.org/10.3747/co.19.1049

APA Style

Hirsh, V. (2012). Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Current Oncology, 19(s1), 86. https://doi.org/10.3747/co.19.1049

Article Metrics

Back to TopTop